Attenuating Atherosclerosis through Inhibition of the NF‐ κ B/NLRP3/IL‐1 β Pathway‐Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)
Cardiovascular Therapeutics · 2024
DOI: 10.1155/2024/1506083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2024. Verfasst von Shihuan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Hubei University of Science and Technology, Xianning 437100, China. Hauptthemen laut MEDLINE: Muscle, Smooth, Vascular, NLR Family, Pyrin Domain-Containing 3 Protein, Myocytes, Smooth Muscle, Pyroptosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
We investigated the effects of resveratrol (Res) and MCC950 on the pyroptosis of vascular smooth muscle cells (VSMCs) and the potential pathway. Methods and Results . Compared with the control (Con) group, the atherosclerosis (AS) group showed calcified nodules, which suggested that the calcification medium induced the calcification of VSMCs. VSMCs showed proliferative activity and significantly attenuated calcification under treatment with 10 μ mol/L Res. The calcium salt was detected by alizarin red S staining. Res and MCC950 downregulated the calcification, inflammatory, pyroptosis, and transcription factor‐related indicators all decreased by RT‐qPCR with Western blot and immunofluorescence. The results showed that Res and MCC950 refrained the calcification of VSMCs and that Res has a better effect than MCC950. Plaques and calcium salt deposits were present in the carotid region in the control group. More calcium salt deposits were evident in the plaques of the Par group by HE staining and alizarin red S staining. The calcification indexes BMP2, Runx2, and related indexes declined by immunofluorescence, which showed parthenolide‐inhibited AS. The related protein expressions were consistent with the expression of the cell experiments.
Conclusion
Our data demonstrated that inflammatory response and pyroptosis exacerbate AS and unravel the link between VSMCs and the progression of AS lesions. Res and MCC950 inhibited the calcification of VSMCs by regulating NF‐ κ B/NLRP3/IL‐1 β signaling axis. P53 can exacerbate the AS lesions by acting on NLRP3 inflammasome and pyroptosis. Our findings supported the clinical applications of Res and MCC950 in VSMCs individuals to counteract pyroptosis and AS, and P53 inhibitors also can be a potential treatment for AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Medicine, Hubei University of Science and Technology, Xianning 437100, China.
- Institute of Medicine, Hubei Key Laboratory of Diabetes, Hubei University of Science and Technology, Xianning, China.
- School of Basic Medical Science, Hubei University of Science and Technology, Xianning, China.
ORCID-Profile: Shihuan Li, Chao Liu, Mincai Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, S., Li, Q., Zhou, Q., Li, S., Wang, S., Yao, Q., Ouyang, C., Liu, C., & Li, M. (2024). Attenuating Atherosclerosis through Inhibition of the NF‐ κ B/NLRP3/IL‐1 β Pathway‐Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs). Cardiovascular Therapeutics. https://doi.org/10.1155/2024/1506083
Vancouver
Li S, Li Q, Zhou Q, Li S, Wang S, Yao Q, et al. Attenuating Atherosclerosis through Inhibition of the NF‐ κ B/NLRP3/IL‐1 β Pathway‐Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs). Cardiovascular Therapeutics. 2024. doi:10.1155/2024/1506083
BibTeX
@article{Li2024,
author = {Li, Shihuan and Li, Qingjie and Zhou, Qiaofeng and Li, Suqin and Wang, Siqi and Yao, Qing and Ouyang, Changhan and Liu, Chao and Li, Mincai},
title = {Attenuating Atherosclerosis through Inhibition of the NF‐ κ B/NLRP3/IL‐1 β Pathway‐Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)},
journal = {Cardiovascular Therapeutics},
year = {2024},
doi = {10.1155/2024/1506083}
}
EUVIMED